Piper Sandler raised the firm’s price target on Myriad Genetics to $30 from $28 and keeps a Neutral rating on the shares. The analyst updated models in the genomic tools and labs group following the Q2 earnings reports.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target raised to $30 from $28 at TD Cowen
- Myriad Genetics price target raised to $29 from $25 at Guggenheim
- Myriad Genetics raises FY24 adjusted EPS view to 8c-12c from 0c-5c
- Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c)
- Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer